Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
ID: 356173Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356173

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-063.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a grant opportunity titled "Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)" aimed at exploring the interactions between microglial pathophysiology and the comorbidity of SUD and HIV. The primary objective is to generate specific microglial protein profiles and interaction networks to understand how HIV-infected microglia contribute to neuropathologies associated with these conditions. This initiative is critical for advancing therapeutic interventions by addressing significant knowledge gaps in the cellular interactions of HIV and substance use disorders. Up to $2.5 million is available for 3-6 awards, with applications due by July 14, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-063.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-25-063.html
    The National Institute on Drug Abuse (NIDA), under the Department of Health and Human Services, announces a funding opportunity (RFA-DA-25-063) focusing on the interaction of microglial pathophysiology in patients with comorbid Substance Use Disorder (SUD) and HIV. This grant aims to explore the protein interaction networks in HIV-infected microglia and their role in cellular signaling disruptions associated with these comorbid conditions. The two-phase approach consists of an R61 phase, where researchers will quantify protein interactions and the R33 phase, extending these analyses to in vivo models. The expectation is to contribute foundational knowledge that may inform future therapeutic interventions. Up to $2.5 million is allocated for 3-6 awards, with eligibility extended to a diverse range of institutions and organizations. Applications are due by July 14, 2025, with stringent adherence to application guidelines required to ensure acceptance. The program seeks to bridge significant knowledge gaps in understanding how HIV and substance use interact at the cellular level, particularly in microglia, to identify viable intervention points for treatment advancements. Ultimately, the initiative aims to leverage advanced protein profiling techniques to address the dual challenges of HIV and substance use disorders effectively.
    Similar Opportunities
    Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)." This initiative aims to investigate the protein interaction networks in HIV-infected microglia and their implications for cellular signaling alterations associated with the coexistence of HIV and SUD, structured in a two-phase approach focusing on both quantitative analytics and in vivo models. The funding, anticipated to be approximately $2.5 million for FY 2026, will support 3-6 awards, with applications opening on July 14, 2025, and a submission deadline of August 14, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research on the Neuro-Immune Axis in the context of HIV and Substance Use," aimed at advancing the understanding of the interplay between neuroimmune networks and the effects of HIV and substance use disorders (SUD). This R01 Clinical Trial Not Allowed grant seeks applications that explore neuroimmune interactions, therapeutic targets, and modulatory tools, with a focus on examining the molecular mechanisms and regulatory pathways influenced by substance use in relation to HIV pathogenesis. The opportunity is significant for addressing HIV-related neurological issues exacerbated by substance abuse, with a total funding of up to $2 million projected for FY 2025 to support up to six projects. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory studies focused on the mechanisms of HIV infection, replication, latency, and pathogenesis in the context of substance use disorders (SUDs). This initiative aims to support high-risk, high-impact research that utilizes innovative tools to investigate the interactions between HIV and addictive substances, with a particular emphasis on understanding the molecular mechanisms involved and the effects of these substances on HIV latency and replication. The total funding budget for this opportunity is $2 million, intended to support three awards, each capped at $700,000 in direct costs annually. Applications are due by July 14, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-011.html.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at supporting exploratory research into the neuroimmune connections related to HIV and substance use disorders. This initiative seeks to identify and characterize neuroimmune networks and communication pathways, as well as discover novel modulatory tools that can enhance understanding of the regulatory mechanisms contributing to the comorbidity of HIV and substance use disorders. The NIH intends to allocate up to $2 million to fund approximately six awards, with individual budgets not exceeding $275,000 over a two-year period. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders," aimed at supporting research into the mechanisms linking autophagy, HIV infection, and substance use disorders. This initiative seeks innovative proposals that explore the interactions between neuroinflammatory responses, neurotransmission, and autophagy, with the goal of identifying therapeutic pathways for intervention. Eligible organizations can apply for up to four grants totaling $2 million, with applications due by November 15, 2024. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-009.html.
    Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 Exploratory/Developmental Research Grant focused on the interplay of autophagy-regulated cell death and HIV pathogenesis in the context of substance use disorders. This funding opportunity aims to enhance understanding of the mechanisms of autophagy and their implications for managing HIV infection and related health issues among individuals with substance use disorders, encouraging innovative mechanistic studies and preclinical research. The grant offers a funding ceiling of $275,000 for a two-year project period, with applications due by November 14, 2024, and awards expected to be announced in early 2025. Interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.